Medscape
The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is the first in its class to show benefits in young children with obesity, according to results from the phase 3a SCALE-KIDS trial presented at the European Association for the Study of Diabetes (EASD) 2024 Annual Meeting and simultaneously published in the New England Journal of Medicine…
Read More
Liraglutide Reduces BMI by Almost 6% in Children Aged 6 to 12
Samatha Antes
23:44
The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is the first in its class to show benefits in young children with obesity, according to results from the phase 3a SCALE-KIDS trial presented at the European Association for the Study of Diabetes (EASD) 2024 Annual Meeting and simultaneously published in the New England Journal of Medicine…
